Arch Biopartners FY26 Q3 net loss widens 99.11% to CAD 475,112
Reuters2026/09/01 00:22- Arch Biopartners posted a net comprehensive loss of CAD 475,112 for the three months ended June 30, widening 96.11%.
- Loss per share widened to CAD 0.007 from CAD 0.004, while operating loss increased to CAD 472,172 from CAD 275,328.
- For the nine months ended June 30, net comprehensive loss widened to CAD 2.56 million from CAD 1.28 million, with no revenue.
- Operating loss widened to CAD 2.55 million from CAD 1.22 million, while cash fell to CAD 2,914 from CAD 167,460.
- Arch said LSALT peptide and cilastatin Phase II trials are ongoing, with its CKD platform in pre-clinical development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
